Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients

뉴스 본문을 불러오고 있어요.

Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients | 웨이프 WAPE

Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients

기사 요약

관련 종목

댓글 —